Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Drug-Device Combinations' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Drug-Device Combinations The Global Market |
January 2010 | £3205 | 100 % |
|
Product Commercialization Excellence: Preparation and Management of Fixed-Dose Combination Drug Products |
October 2008 | £3380 | 63 % |
|
Medical Device Development Regulation and Law |
September 2009 | £160 | 50 % |
|
Launching Combination Products Brand Extension and Franchise Development Strategies |
January 2008 | £1995 | 41.5 % |
|
Food-Drug Synergy and Safety |
August 2005 | £74.99 | 40 % |
|
Handbook of Chronic Total Occlusions |
July 2007 | £90 | 35 % |
|
Alzheimer's Disease Current Treatment Practices and Opportunities, 2010 |
February 2010 | £2999 | 34.3 % |
|
Combinatorx Incorporated Premium Company Profile |
December 2007 | £175 | 32 % |
|
Bevacizumab: Extended Country Coverage Pipeline Selector |
Ongoing | £625 | 31.5 % |
|
Bevacizumab: Core Country Coverage Pipeline Selector |
Ongoing | £270 | 31.5 % |
|
China Pharmaceutical Regulatory Report 2009 |
January 2009 | £1020 | 29.05 % |
|
Pharmaceutical Biotechnology Drug Discovery and Clinical Applications |
February 2004 | £115 | 29 % |
|
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology |
November 2007 | £1755 | 28 % |
|
Stakeholder Opinions: Portable Inhaler Devices Key Tools To Differentiate Brands and Survive Generic Pressure |
April 2008 | £1320 | 27.65 % |
|
Cancer Antibodies Competitive Positioning for Success |
June 2008 | £1745 | 27 % |
|
Cancer Antibodies: Competitive Positioning for Success |
June 2008 | £1745 | 27 % |
|
Stakeholder Insight Asthma - over-Prescribing Is Common in Intermittent and Mild Forms of Asthma |
July 2008 | £5020 | 26.95 % |
|
Cancer Vaccines: Aim and Shoot |
May 2008 | £1745 | 26.5 % |
|
Neuropathic Pain: Emerging Drugs and Current Treatment Practices |
February 2010 | £2999 | 24.5 % |
|
Pipeline Insight: Asthma/COPD Targeted therapies on the horizon |
November 2006 | £3965 | 24.15 % |
|
Injectable Drug Delivery: Market Impact and Industry Trends |
October 2006 | £1155 | 24 % |
|
Baxter International Medical Device Company Intelligence Report |
March 2009 | £295 | 24 % |
|
Hypertension - Treatments and Prescribing Practices A Global Survey 2009 |
October 2009 | £4165 | 23.8 % |
|
Abacavir: Core Country Coverage Pipeline Selector |
Ongoing | £270 | 23.5 % |
|
Abacavir: Extended Country Coverage Pipeline Selector |
Ongoing | £625 | 23.5 % |
|
Tenofovir: Core Country Coverage Pipeline Selector |
Ongoing | £270 | 23.5 % |
|
Tenofovir: Extended Country Coverage Pipeline Selector |
Ongoing | £625 | 23.5 % |
|
Drug Repositioning Strategies Innovative Strategies To Boost Pipeline Productivity |
June 2007 | £1495 | 23.45 % |
|
Understanding Pharmacogenomics Maximum Efficacy with Minimal Adverse Effects |
January 2009 | £395 | 23 % |
|
Sitagliptin: Core Country Coverage Pipeline Selector |
Ongoing | £270 | 23 % |
|
Sitagliptin: Extended Country Coverage Pipeline Selector |
Ongoing | £625 | 23 % |
|
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents |
October 2006 | £3090 | 22.5 % |
|
Efavirenz: Extended Country Coverage Pipeline Selector |
Ongoing | £625 | 22.5 % |
|
Efavirenz: Core Country Coverage Pipeline Selector |
Ongoing | £270 | 22.5 % |
|
Treating Neuropathic Pain A Global Study of Clinical Strategies |
January 2010 | £1999 | 22.4 % |
|
Pharmaceutical Supply Chain Strategies Reassessing Product Distribution to Cut Costs and Improve Supply Chain Management |
March 2008 | £1320 | 22 % |
|
Pharmaceutical Product Relaunch Preserving Market Share through Line Extension and New Market Entry Strategies |
April 2007 | £5080 | 21.7 % |
|
Corporate Security Protecting Productivity |
December 2007 | £4620 | 21.7 % |
|
Combating Generics Counter-Generics Strategy, Tactics and Execution |
December 2007 | £2175 | 21.7 % |
|
Crisis Management And Corporate Reputation Counter-Generics Strategy, Tactics and Execution |
November 2007 | £4620 | 21.7 % |
|
Targeting Cancer Stem Cells Emerging Therapeutic, Therapeutic Strategies and Pipeline Developments (2010) |
January 2010 | £1599 | 21.5 % |
|
The Dermatology Market Outlook to 2013 Competitive Landscape, Pipeline Analysis and Growth Opportunities |
October 2008 | £2025 | 20.3 % |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC |
July 2007 | £2475 | 20 % |
|
Who's Developing What in Drug Delivery? |
November 2009 | £595 | 19.5 % |
|
Cordis Medical Device Company Intelligence Report |
August 2009 | £195 | 19.5 % |
|
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies |
July 2007 | £945 | 19 % |
|
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer |
March 2006 | £3090 | 19 % |
|
World Market for Prescription Cardiovascular Drugs 2nd Edition |
November 2007 | £2640 | 18.9 % |
|
Uzbekistan Pharmaceuticals and Healthcare Report Q1 2010 |
November 2009 | £250 | 18.9 % |
|
Commercial and Pipeline Insight: Hepatitis B |
October 2007 | £5020 | 18.9 % |
|
Analytical Tool: Competitive Outlook on HCV |
July 2004 | £1345 | 18.5 % |
|
Moldova Pharmaceuticals and Healthcare Report Q1 2009 |
February 2009 | £250 | 18.2 % |
|
Current and Future Therapies for Lung Cancer A Therapeutic & Competitive Insight |
March 2006 | £1745 | 18 % |
|
Major World Markets for Stents and The Economics of Drug-Eluting Technology |
May 2008 | £1850 | 18 % |
|
Pharmaceutical Pricing and Distribution in Japan The keys to success in the world's second largest market |
June 2008 | £1450 | 17.5 % |
|
Targeted Therapeutics in Non-Small Cell Lung Cancer |
April 2007 | £1400 | 17.5 % |
|
New Drug Futures: Respiratory Chapter |
May 2006 | £695 | 17.5 % |
|
The Global Market for Pain Management Drugs and Devices |
August 2009 | £3205 | 17.5 % |
|
Stakeholder Opinions: Female Sexual Dysfunction Results from Datamonitor's 2005 physician survey |
June 2007 | £1325 | 17.5 % |
|
World Asthma and COPD Treatment Market, 2006-2011, The A Changing Market with Increasing Potential |
September 2006 | £1499 | 17.5 % |
|
Cancer Drug Resistance 2008 |
September 2008 | £1675 | 17.15 % |
|
Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery |
November 2006 | £1495 | 17.15 % |
|
Chronic Obstructive Pulmonary Disease |
February 2010 | £2280 | 17.15 % |
|
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011 |
June 2006 | £1495 | 17.15 % |
|
Currently Druggable in Melanoma A Drug Target Competitive Analysis |
October 2008 | £1745 | 17.15 % |
|
Protease Inhibitors Innovation Drives Drug Pipeline |
February 2009 | £2475 | 17 % |
|
Commercial Insight: Asthma & COPD |
June 2009 | £10040 | 16.8 % |
|
Conducting Medical Device Trials in the EU |
January 2007 | £1300 | 16.8 % |
|
BioMimetic Therapeutics, Inc. - Financial and Strategic Analysis Review |
June 2009 | £83 | 16.5 % |
|
Ion Channel Drug Discovery Therapeutic Opportunities & Technology Progress |
May 2004 | £895 | 16.5 % |
|
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology |
December 2006 | £4635 | 16.5 % |
|
Prostate Cancer Drug Discoveries What The Future Holds |
November 2009 | £1295 | 16.5 % |
|
Biomarkers Technologies, Markets and Companies |
March 2010 | £2970 | 16.5 % |
|
U.S. Market for Over-the-Counter Pediatric Medication and Healthcare Products |
March 2006 | £1980 | 16.45 % |
|
Currently Druggable in Colorectal Cancer A Drug Target Competitive Analysis |
December 2008 | £1745 | 16.45 % |
|
Currently Druggable in Prostate Cancer A Drug Target Competitive Analysis |
September 2008 | £1745 | 16.1 % |
|
Global Diabetes Market; The Therapeutics, Diagnostics and Complications |
August 2006 | £1650 | 16.1 % |
|
Top 10 Medical Equipment Market Trends |
May 2008 | £2310 | 16.1 % |
|
Stakeholder Opinions: Hepatocellular Carcinoma Opportune indication for novel therapies |
June 2007 | £2510 | 16.1 % |
|
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope Healthcare |
March 2009 | £1320 | 16 % |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1745 | 15.75 % |
|
Currently Druggable in Breast Cancer A Drug Target Competitive Analysis |
August 2008 | £1745 | 15.75 % |
|
Pipeline Insight: Colorectal Cancer Growing trend towards personalized medicine |
October 2009 | £7530 | 15.75 % |
|
Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of life Healthcare |
March 2009 | £1320 | 15.75 % |
|
Global Markets for Asthma and COPD Drugs |
October 2009 | £3205 | 15.75 % |
|
Commercial Insight: Asthma & COPD Combination Products Still Have Blockbuster Potential |
July 2007 | £5020 | 15.75 % |
|
Competitor Analysis: Targeted Therapy of Hepatitis C |
August 2009 | £450 | 15.5 % |
|
CNS Drug Discoveries: Multiple Sclerosis |
November 2006 | £795 | 15.5 % |
|
Moldova Pharmaceuticals and Healthcare Report Q1 2010 |
November 2009 | £250 | 15.4 % |
|
The Global Antivirals Market R&D Pipelines, Market Analysis and Competitive Landscape |
May 2007 | £1650 | 15.4 % |
|
Reporting Adverse Events |
September 2006 | £75 | 15.05 % |
|
Forecast Insight: Dyslipidemia - Genericization and negative trial data drive market shrinking |
August 2008 | £5020 | 15.05 % |
|
Competitive Outlook on HCV What to Know & Expect in R&D and Business Development |
June 2004 | £895 | 15 % |
|
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology |
October 2006 | £1745 | 15 % |
|
Alzheimer's Disease:Markets, Pipeline and Opportunities 2009 |
April 2009 | £1855 | 15 % |
|
Pipeline Insight: Hepatitis C Protease inhibitors to drive market expansion |
June 2006 | £4290 | 14.7 % |
|
Clinical Trial Supply |
January 2007 | £595 | 14.7 % |
|
Stakeholder Opinions: Ovarian Cancer Growing importance as secondary indication for targeted therapies |
July 2006 | £1450 | 14.7 % |
|
Approaches to Reducing Phase II Attrition |
May 2009 | £2475 | 14.5 % |
|
Stakeholder Insight: COPD - Another Reason to Quit |
December 2005 | £5745 | 14.5 % |
|
Obesity Drug Discoveries: what the future holds |
August 2007 | £1425 | 14.35 % |
|
Systems Biology A Disruptive Technology |
May 2008 | £745 | 14.35 % |
|
MarketWatch: Health Roundup |
November 2008 | £140 | 14.35 % |
|
Obesity Drug Discoveries: what the future holds + Obesity Tracker |
August 2007 | £1425 | 14.35 % |
|
Multiple Sclerosis World Market Outlook to 2011 |
June 2007 | £1980 | 14 % |
|
World Respiratory Disorders Market 2009-2024 |
June 2009 | £1499 | 14 % |
|
Anti-Infectives World Market, 2nd. Ed., Vol. I |
March 2007 | £1980 | 14 % |
|
Distribution and Patient Support for Speciality Medicines in Europe |
September 2009 | £650 | 14 % |
|
Stakeholder Opinions: Percutaneous Coronary Intervention Adverse events with drug-eluting stents demand a new safety standard |
April 2008 | £1320 | 13.65 % |
|
Switzerland Pharmaceuticals and Healthcare Report Q1 2009 |
January 2009 | £250 | 13.5 % |
|
Cancer Biomarkers: Adoption Is Driving Growth |
July 2008 | £2475 | 13.5 % |
|
Pre-Launch Planning Priming Your Pharmaceutical Brand for Profit and Success |
November 2008 | £997 | 13.5 % |
|
Bioinformatics Opportunities Business models, trends and future challenges |
May 2004 | £2500 | 13.5 % |
|
Chronic Obstructive Pulmonary Disease (COPD) Drug Pipeline Analysis and Market Forecasts to 2016 |
February 2010 | £1320 | 13.5 % |
|
Stakeholder Insight: Osteoporosis Generic alendronate further establishes oral bisphosphonates as gold standard |
October 2008 | £5285 | 13.3 % |
|
Delivery Mechanisms for Large Molecule Drugs Successes and Failures of Leading Technologies and Key Drivers for Market Success |
January 2009 | £2025 | 13.3 % |
|
Pipeline Insight: Breast Cancer Recent approvals increase pressure on pipeline candidates |
April 2008 | £3965 | 13.3 % |
|
Drug Delivery Series I-IV |
April 2007 | £4720 | 13.3 % |
|
Medical Device Coatings |
November 2008 | £3205 | 13.3 % |
|
Companion Animal Behavioral Products |
January 2007 | £895 | 13.3 % |
|
Product Lifecycle Management, 2006 |
May 2006 | £1499 | 13.3 % |
|
Drug Delivery Technologies: Players, products & prospects to 2015 |
November 2007 | £1795 | 13 % |
|
Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments World Market |
May 2007 | £1320 | 13 % |
|
Pharmaceutical Regulatory Industry |
January 2006 | £2885 | 12.95 % |
|
Indication Expansion Opportunities for successful lifecycle management |
March 2007 | £1495 | 12.95 % |
|
The Global HIV/Aids Market Outlook To 2012 |
July 2007 | £1495 | 12.95 % |
|
Diabetes Drug Discoveries 2009: what the future holds |
February 2009 | £795 | 12.95 % |
|
Diabetes, Metabolic Syndrome and Cardiovascular Disease Reshaping Tomorrow's Diabetes Market |
April 2009 | £2245 | 12.95 % |
|
Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines |
December 2006 | £5285 | 12.95 % |
|
The Dermatology Market Outlook to 2011 |
March 2007 | £1495 | 12.6 % |
|
Stakeholder Opinions: Bladder Cancer New drugs needed to challenge ineffective 20 year old drugs |
November 2008 | £1320 | 12.6 % |
|
Renal Cell Carcimona Drug Discoveries - what the future holds |
February 2010 | £1295 | 12.5 % |
|
Blockbuster Pharmaceutical Launches Establishing Market Leadership |
May 2006 | £2175 | 12.5 % |
|
Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos Healthcare |
March 2009 | £1320 | 12.25 % |
|
eSampling Strategies Using Internet Technologies to Increase Impact at the Point of Care |
October 2006 | £1325 | 12.25 % |
|
Global Ophthalmic Market Analysis & Forecasts to 2012 |
April 2007 | £1499 | 12.25 % |
|
Competitive Outlook on Non-Antibody Based Cancer Vaccines |
August 2006 | £1745 | 12.25 % |
|
Anesthesia Drugs Worldwide Markets |
July 2007 | £1980 | 12.25 % |
|
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
April 2008 | £3965 | 12.25 % |
|
Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals), The |
October 2009 | £2310 | 12.25 % |
|
Top 100 Best Pharma Outsourcing Service Providers in China and India |
July 2009 | £625 | 12 % |
|
Alzheimer's Disease Biomarkers, 2009 |
January 2009 | £1499 | 12 % |
|
Competitor Analysis: EGF-R Agonists and Antagonists |
October 2009 | £270 | 12 % |
|
Biopartnering Strategies Maximizing returns from biotechnology deal-making |
December 2006 | £1495 | 12 % |
|
Diabetes Drug Discoveries What the Future Holds |
January 2007 | £1495 | 12 % |
|
Reissuing pharmaceuticals in the NHS Challenging the chain of trust |
October 2005 | £600 | 12 % |
|
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology |
December 2006 | £3090 | 11.9 % |
|
Glaucoma Pharmaceuticals |
February 2010 | £2610 | 11.9 % |
|
The Cardiovascular Disorders Market Outlook to 2012 |
February 2008 | £1995 | 11.9 % |
|
Forecast Insight: HIV |
June 2009 | £10040 | 11.9 % |
|
Pipeline Insight: Depression Novel drugs to grow third-line market |
March 2007 | £3965 | 11.9 % |
|
Stakeholder Opinions: Fibromyalgia Potentially lucrative market soon to become reality |
May 2007 | £1325 | 11.9 % |
|
Pipeline Insight: Antiarrhythmics RSD1235 in a class of its own |
May 2006 | £4290 | 11.9 % |
|
Generic Series: Optimizing Brand Lifecycle Management Winning Strategies to Maximize Revenue in The Face of Growing Generic Competition |
July 2008 | £2510 | 11.9 % |
|
Cancer Therapeutics Market Insight and R&D Pipeline Analysis |
August 2008 | £2310 | 11.55 % |
|
Commercial and Pipeline Insight: Opioids Short Acting and Anti-Abuse Technologies Set to Fragment and Grow The Market |
March 2008 | £5020 | 11.55 % |
|
Managing Antimicrobial Resistance |
August 2007 | £115 | 11.55 % |
|
Stakeholder Opinion: Erectile Dysfunction Identifying product differentiation and patient segmentation strategies |
December 2006 | £1325 | 11.55 % |
|
Interventional Cardiology Clinical Trial Analysis |
July 2009 | £660 | 11.55 % |
|
Transdermal Drug Delivery Technologies, Markets and Companies |
March 2010 | £1850 | 11.55 % |
|
Drug Repositioning A market analysis |
March 2006 | £1095 | 11.5 % |
|
Ensuring Profitable Patient Adherence Programs Using Analytics and Metrics to Improve the Bottom Line |
March 2008 | £497 | 11.5 % |
|
Melanoma Drug Pipeline Analysis and Market Forecasts to 2015 |
December 2009 | £1320 | 11.5 % |
|
Abbott Laboratories: PharmaVitae Profile Healthcare |
September 2009 | £3765 | 11.2 % |
|
Pipeline Insight: HIV Extending treatment options |
September 2006 | £3965 | 11.2 % |
|
Antibiotic R&D Resolving the Paradox between Unmet Medical Need and Commercial Incentive |
July 2008 | £2475 | 11.2 % |
|
U.S. Market for Prescription Ophthalmic Drugs, Devices, Diagnostics, and Surgical Equipment, The |
September 2006 | £2885 | 11.2 % |
|
Ophthalmological Therapeutics Pipelines, Delivery Technologies, and Markets |
January 2008 | £745 | 11.2 % |
|
Anti Addiction Therapies, 2006-2011- The Pharmaceutical Industry's Next Viagra? |
October 2006 | £1499 | 11 % |
|
Commercial Insight: Osteoporosis Risk management and reformulation offer best defense against generic onslaught |
June 2007 | £5020 | 11 % |
|
Latvia Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 11 % |
|
IGF-1R Antagonists Competitor Analysis |
July 2009 | £225 | 11 % |
|
Biogen Idec: Pipeline - Products - Performance - Potential |
January 2010 | £595 | 11 % |
|
Stakeholder Opinions: Asthma Phenotypes A changing paradigm |
March 2007 | £1325 | 10.85 % |
|
Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth |
April 2009 | £3965 | 10.85 % |
|
CompuMed, Inc. Product Pipeline Analysis |
August 2008 | £495 | 10.85 % |
|
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry |
April 2009 | £3965 | 10.85 % |
|
Pharmaceuticals in China |
February 2006 | £3170 | 10.85 % |
|
Reformulation Strategies Comparisons of Past and Future Reformulation Strategies |
September 2006 | £2640 | 10.85 % |
|
Cardiovascular Generic Drugs Prospects and Opportunities to 2012 |
December 2007 | £995 | 10.85 % |
|
The Top 100 Molecular Diagnostics Manufacturing Companies Worldwide |
March 2009 | £625 | 10.85 % |
|
The Cancer Market Outlook To 2014 Competitive landscape, market size, pipeline analysis and growth opportunities |
January 2010 | £3835 | 10.85 % |
|
The Autoimmune Outlook to 2013 Competitive landscape, pipeline analysis and growth opportunities |
April 2009 | £2025 | 10.85 % |
|
The Future of HIV Therapeutics Market Forecasts to 2015 |
December 2009 | £2310 | 10.85 % |
|
Pharmaceutical Pricing and Reimbursement Reference Pricing and Economic Evaluations Will Dominate Future Pricing and Reimbursement Strategies |
February 2010 | £2310 | 10.5 % |
|
Pipeline Insight: Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline |
May 2008 | £3965 | 10.5 % |
|
Preventive Healthcare Technologies, Products and Markets |
October 2009 | £3205 | 10.5 % |
|
Innovations in Cardiovascular Disease Management Latest surgical procedures, drugs and medical devices |
September 2007 | £1495 | 10.5 % |
|
Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs Healthcare |
March 2009 | £1320 | 10.5 % |
|
Therapies for Depressive and Anxiety Disorders |
February 2010 | £3205 | 10.5 % |
|
Financial Markets Research: ASCO Review Part II A summary of highlights presented at the ASCO 2006 Annual Meeting |
August 2006 | £1450 | 10.5 % |
|
Pediatric Drugs: the Worldwide Market 3rd Edition |
December 2007 | £2640 | 10.5 % |
|
R&D Pipeline News - Therapeutic Area Edition: 1-Month Subscription Periodical |
October 2008 | £90 | 10.5 % |
|
The CNS Market Outlook to 2013 Competitive landscape, pipeline analysis and growth opportunities |
September 2008 | £1995 | 10.5 % |
|
Competitor Analysis: Biologic and Immune Therapy of S. aureus Infections |
March 2010 | £180 | 10.5 % |
|
Stakeholder Opinions: Head and Neck Cancer Innovatives to Change the Face of Treatment |
November 2007 | £1325 | 10.5 % |
|
Hepatitis C Virus and Therapeutics A Global Update of Market Trends & Opportunities |
November 2009 | £1980 | 10.15 % |
|
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023 |
May 2008 | £1499 | 10.15 % |
|
Drug Delivery in Cancer Technologies, Markets and Companies |
March 2010 | £2310 | 10.15 % |
|
Anti Infectives, Vol II: Antibacterials |
April 2007 | £1980 | 10.15 % |
|
Antiviral Therapeutics Technologies, Markets and Companies |
March 2010 | £2115 | 10.15 % |
|
Drug Treatments for Leading Endocrine and Metabolic Diseases |
February 2007 | £2885 | 10.15 % |
|
Medical Plastics |
November 2006 | £2885 | 10.15 % |
|
Pipeline And Commercial Insight Pediatric And Adolescent Vaccines |
July 2007 | £5285 | 10.15 % |
|
Japan Approvals Database (JAD) Master File + Master Files Overview |
Ongoing | £530 | 10 % |
|
HDAC Inhibitors Competitor Analysis |
July 2009 | £360 | 10 % |
|
Biogen Idec Pipeline Products Performance Potential |
March 2008 | £595 | 10 % |
|
Mitsubishi Tanabe Pharma Corporation - Financial and Strategic Analysis Review |
July 2009 | £83 | 10 % |
|
Infectious Disease Diagnostic Markets |
August 2009 | £2310 | 10 % |
|
ASCO 2009: Significant Developments in Context |
July 2009 | £595 | 9.8 % |
|
Pricing and Reimbursement in Japan Costly healthcare system inefficiencies increase the focus on healthcare cost containment |
November 2006 | £1325 | 9.8 % |
|
Women's Reproductive Disorders Therapeutics 2008-2018 |
September 2008 | £1499 | 9.8 % |
|
Multiple Myeloma Therapeutics US Market Trends & Analysis |
November 2009 | £1980 | 9.8 % |
|
Drug Discovery Tools for High-Content Analysis |
July 2007 | £1320 | 9.8 % |
|
The Future of Monoclonal Antibodies Therapeutics Innovation in antibody engineering, key growth strategies and forecasts to 2011 |
July 2006 | £1495 | 9.8 % |
|
Comparison of Pharma Outsourcing between China and India |
July 2009 | £990 | 9.5 % |
|
Global Protein Therapeutics Market, The Market Dynamics and Pipeline Analysis |
December 2006 | £1980 | 9.5 % |
|
Colombia Pharmaceuticals and Healthcare Report Q1 2009 |
February 2009 | £250 | 9.5 % |
|
Croatia Pharmaceuticals and Healthcare Report Q1 2010 |
November 2009 | £250 | 9.5 % |
|
Cell-Based Assays for Drug Discovery |
August 2009 | £2245 | 9.45 % |
|
Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The |
January 2007 | £1485 | 9.45 % |
|
The Asian Cardiovascular Market Outlook to 2014 Regional and therapeutic analysis, pipeline impact and growth opportunities |
March 2009 | £2025 | 9.45 % |
|
Epigenomics Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics |
March 2007 | £3205 | 9.45 % |
|
World Allergy Market 2006-2011, The The Rx-OTC Rush |
October 2006 | £1499 | 9.45 % |
|
Enzyme Inhibitors with Broad Therapeutic Applications |
June 2006 | £2885 | 9.45 % |
|
Stakeholder Insight: Non-Small Cell Lung Cancer The need for greater product differentiation in an increasingly crowded market |
November 2006 | £5285 | 9.45 % |
|
Herbal Supplements, Prescription Drugs, Rx-to-OTC Products A Comparison |
October 2006 | £2885 | 9.45 % |
|
Cardiotoxicity: Issues, Technologies, and Solutions for the Future |
May 2008 | £2475 | 9.45 % |
|
Commercial Insight: Antidiabetics in Australia Reimbursement status shapes novel classes |
October 2009 | £3765 | 9.1 % |
|
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation |
November 2008 | £5285 | 9.1 % |
|
Stakeholder Insight: Psoriasis Biologics are yet to make topical treatments obsolete |
March 2009 | £5285 | 9.1 % |
|
Pharmacogenomics: New Technologies In the Development of Personalized Therapies |
August 2005 | £2885 | 9.1 % |
|
Global Generics Guide: Part 2 Benchmarking country markets and strategic issue |
June 2006 | £5745 | 9.1 % |
|
Commercial Insight: Depression Atypical lifecycle management strategy rejuvenates depression market |
June 2007 | £5020 | 9.1 % |
|
Ranbaxy Generics Company Intelligence Report Company Intelligence Report |
March 2009 | £195 | 9.1 % |
|
Diabetes and Diabetic Complications Major World Markets, 3rd Ed. |
March 2007 | £2640 | 9.1 % |
|
Emerging Markets For Microfluidic Applications EMMA Report 2009 Emerging Markets for Microfluidic Applications in Life Sciences and In-Vitro Diagnostics |
August 2009 | £3575 | 8.75 % |
|
Gastrointestinal Pharmaceuticals: Technologies and Markets |
September 2009 | £3205 | 8.75 % |
|
What's Hot in Cancer Drug R&D? |
July 2006 | £295 | 8.75 % |
|
Business Blogging for Pharma |
August 2007 | £1325 | 8.75 % |
|
Stakeholder Perspectives: Pulmonary Arterial Hypertension A small market gets big attention |
February 2006 | £2875 | 8.75 % |
|
The World Market for Gynaecology 2007-2017 |
September 2007 | £3200 | 8.75 % |
|
Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs |
May 2007 | £995 | 8.75 % |
|
Molecular Imaging in Drug R&D and Medical Practice Technologies, Applications, Markets |
January 2008 | £745 | 8.75 % |
|
Breast Cancer Drug Discoveries What the future holds |
December 2008 | £795 | 8.75 % |
|
Cardiovascular Drug Delivery Technologies, Markets and Companies |
March 2010 | £1650 | 8.75 % |
|
Pharmaceutical Regulatory Affairs in The Eu & US |
January 2006 | £1095 | 8.75 % |
|
R&D Pipeline News - Therapeutic Area Edition: 1-Year Subscription Periodical |
October 2008 | £715 | 8.5 % |
|
R&D Pipeline News - Technology Edition: 1-Month Subscription Periodical |
October 2008 | £90 | 8.5 % |
|
R&D Pipeline News - Technology Edition: 1-Year Subscription Periodical |
October 2008 | £715 | 8.5 % |
|
PI3K-Akt-mTOR Pathway Inhibitors Competitor Analysis |
July 2009 | £450 | 8.5 % |
|
Targeted Therapies in Oncology A World Review |
December 2006 | £4435 | 8.4 % |
|
Stakeholder Insight: Respiratory Tract Infections in the USA The demise of narrow-spectrum antibiotics |
November 2006 | £5285 | 8.4 % |
|
Stakeholder Insight: Respiratory Tract Infections in the USA The demise of narrow-spectrum antibiotics |
November 2006 | £8000 | 8.4 % |
|
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology |
August 2006 | £3090 | 8.4 % |
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline |
October 2006 | £5285 | 8.4 % |
|
Generics in Japan |
November 2009 | £1825 | 8.4 % |
|
Market for Bioengineered Protein Drugs; The |
January 2007 | £2885 | 8.4 % |
|
Pricing & Reimbursement in Asia-Pacific |
January 2006 | £1095 | 8.4 % |
|
Commercial Insight: Antidyslipidemics Branded statins beware, generics are amongst you |
July 2006 | £5575 | 8.4 % |
|
Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment |
June 2007 | £5020 | 8.4 % |
|
Commercial Insight: Antidyslipidemics The competitive cost-conscious antidyslipidemics market presents challenges |
July 2007 | £5020 | 8.4 % |
|
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit |
July 2007 | £3965 | 8.05 % |
|
Pipeline Insight: Anxiety Disorders A decade of declining revenues |
March 2006 | £4290 | 8.05 % |
|
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome Reformulations set to drive near-term growth |
August 2006 | £5745 | 8.05 % |
|
Cancer Therapies Global Market Opportunities |
November 2009 | £1980 | 8.05 % |
|
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries |
July 2007 | £5020 | 8.05 % |
|
Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics |
November 2008 | £1195 | 8 % |
|
Advances in Molecular Imaging Companies and Technologies that are driving change |
February 2010 | £695 | 8 % |
|
Nanobiotechnology Applications, Markets and Companies |
March 2010 | £2970 | 7.7 % |
|
Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed |
September 2007 | £5020 | 7.7 % |
|
Proteomics Technologies, Markets and Companies |
March 2010 | £2970 | 7.7 % |
|
Stakeholder Opinions: Parkinson's Disease Review of Key Commercial Opportunities in the Symptomatic Treatment Market |
July 2006 | £1395 | 7.7 % |
|
Blood Typing, Grouping and Infectious Disease Screening Tests Analysis of Current and Emerging Assays and Companies Developing New Technologies and Products |
September 2009 | £1455 | 7.7 % |
|
Medical Imaging Markets, Volume IV Contrast Agents |
February 2007 | £1980 | 7.7 % |
|
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth |
October 2008 | £5285 | 7.7 % |
|
Disease Specific Markers Clinical Trial Analysis |
July 2009 | £660 | 7.7 % |
|
Anti-Hypertensive Drugs |
February 2010 | £2610 | 7.7 % |
|
Pharmaceutical Regulatory Affairs in the EU and US |
December 2006 | £1095 | 7.7 % |
|
Tumour Markers Clinical Trial Analysis |
July 2009 | £660 | 7.7 % |
|
Stakeholder Opinions: Bone Metastases Impending Patent Expiries May Help Make or Break Newer Agents |
March 2008 | £1320 | 7.35 % |
|
Preclinical Cancer Therapeutics 2007 Decoding Next Generation Drug Targets for Market Success |
December 2006 | £1600 | 7.35 % |
|
Current and Emerging Infectious Disease Tests Emerging Assays and Companies Developing New Technologies and Products |
November 2009 | £0 | 7.35 % |
|
Top 7 Cancer Indications Therapeutic & Competitive Insights |
January 2007 | £6225 | 7.35 % |
|
Radiopharmaceuticals A US and European Market Analysis |
November 2009 | £1980 | 7.35 % |
|
Stakeholder Opinions: Cancer Cachexia Higher profile needed to unlock market potential of neglected syndrome |
January 2009 | £1320 | 7.35 % |
|
Global Antivirals Market Analysis & Forecasts 2008-2023 |
September 2008 | £1499 | 7.35 % |
|
Epigenetics |
February 2010 | £2970 | 7 % |
|
Stakeholder Opinions: Primary Brain Cancer Temozolomide Turns Heads |
July 2007 | £1320 | 7 % |
|
Commercial Insight: Migraine Opportunities Will Exist In The Wake Of Generic Attack |
September 2007 | £5020 | 7 % |
|
Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics 2009-2023 |
January 2009 | £1499 | 7 % |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £1980 | 7 % |
|
Innovations In Epigenetics Advances in Technologies, Diagnostics & Therapeutics |
November 2009 | £3835 | 7 % |
|
Commercial and Pipeline Insight: Systemic antifungals |
November 2007 | £5020 | 7 % |
|
Parkinson's Disease Market analysis and forecasts 2008-2012, 2017 & 2022 |
January 2008 | £1499 | 7 % |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £1980 | 7 % |
|
Anti-Infectives |
February 2010 | £2610 | 7 % |
|
The World Dermatological Market Outlook 2010-2024 |
November 2009 | £1499 | 7 % |
|
HIV: A Strategic Analysis of Therapeutic and Testing Markets |
March 2006 | £2310 | 6.65 % |
|
RNAi Technologies, Markets and Companies |
March 2010 | £2310 | 6.65 % |
|
Stakeholder Insight: Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge |
October 2006 | £5285 | 6.65 % |
|
Launch Strategies - Analyzing Market Trends and Regulatory Impacts |
August 2007 | £5290 | 6.65 % |
|
Stakeholder Opinions: Acute Leukemias Persistent unmet needs confer significant commercial opportunity |
April 2006 | £1435 | 6.65 % |
|
Lung Cancer Therapeutics |
July 2009 | £2610 | 6.65 % |
|
The World Antibacterial Treatments Market 2010-2024 |
December 2009 | £1499 | 6.65 % |
|
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer |
June 2007 | £2475 | 6.65 % |
|
Immunomodulators Therapeutic Needs, Pipelines & Prospects |
August 2007 | £1495 | 6.65 % |
|
Early Stage and Discovery Deals Strategy, Structure and Payment Terms 2nd Edition |
December 2006 | £1880 | 6.65 % |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £3965 | 6.3 % |
|
New Dynamics and Challenges in The Generics Market 2007 |
January 2007 | £1870 | 6.3 % |
|
Angiotech Pharmaceuticals, Inc. Product Pipeline Analysis |
August 2008 | £495 | 6.3 % |
|
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 |
June 2007 | £1999 | 6.3 % |
|
Live-Licensing & In-life Testing R&D Processes and Regulation for New Drugs, 2008-2020 |
January 2008 | £1499 | 6.3 % |
|
U.S. Market for Gastrointestinal Pharmaceuticals |
September 2005 | £2885 | 6.3 % |
|
The Future of The Diabetes Care Devices Market to 2016 The Key Demand Drivers Remain Intact |
January 2010 | £2310 | 6.3 % |
|
Smoking Cessation Report 2009-2024 |
February 2009 | £1499 | 6.3 % |
|
Pediatric Health Care Products and Services |
March 2009 | £3205 | 6.3 % |
|
Pipeline/Commercial Insight: Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications |
June 2007 | £5020 | 6.3 % |
|
Stakeholder Insight: Metabolic Syndrome Multiple definitions complicate treatment |
April 2006 | £5740 | 5.95 % |
|
Computed Tomography Systems Clinical Trial Analysis |
July 2009 | £660 | 5.95 % |
|
Small Molecule Kinase Inhibitors |
July 2009 | £2610 | 5.95 % |
|
Gastrointestinal Disorders Market Intelligence to 2012 |
May 2007 | £1499 | 5.95 % |
|
The Future of Metabolic Disorder Therapeutics Market Forecasts to 2015 |
December 2009 | £2310 | 5.95 % |
|
Commercial Insight: Antihypertensives New challenges for a maturing market |
September 2006 | £5285 | 5.95 % |
|
Fastest Growing Biotechnology Companies, The Growth Strategies, Comparative Analyses and Company Profiles |
March 2008 | £1995 | 5.6 % |
|
Cancer Cell Therapy Markets |
March 2008 | £2245 | 5.6 % |
|
Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential Healthcare |
March 2009 | £5285 | 5.6 % |
|
Growth Factors (Blood and Tissue) A World Report |
November 2009 | £1980 | 5.6 % |
|
IND: Submissions |
February 2009 | £195 | 5.6 % |
|
Pain Therapeutics Drugs, Markets and Companies |
March 2010 | £2310 | 5.6 % |
|
Women's Health Worldwide Prescription Drug Markets |
August 2006 | £1300 | 5.25 % |
|
Antibiotics and Drug Resistance 2008 Drug Innovation and the Strategy to Combat - Antibiotic Resistance Mechanisms |
January 2008 | £1499 | 5.25 % |
|
The US Blood Banking Market through 2013 |
September 2009 | £4490 | 5.25 % |
|
Cytogenetics Technologies, Markets and Companies |
March 2010 | £1455 | 5.25 % |
|
Pipeline Insight: Nosocomial Vaccines Minefield or Goldmine? |
April 2008 | £3965 | 5.25 % |
|
Gene Therapy Technologies, Markets and Companies |
March 2010 | £2970 | 5.25 % |
|
Facial Rejuvenation Markets Worldwide |
August 2008 | £1310 | 5.25 % |
|
Commercial Insight: Select Herpes Viruses and Human Papilloma Virus Non-Biologic Interventions for Oral and Genital Herpes, Cytomegalovirus Infection, Herpes Zoster and Genital Warts |
August 2008 | £5020 | 5.25 % |
|
Women's Health Worldwide Prescription Drug Markets |
August 2006 | £2575 | 5.25 % |
|
EMI/RFI: Materials and Technologies |
June 2007 | £3205 | 5.25 % |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1850 | 4.9 % |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £1980 | 4.9 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
February 2010 | £2115 | 4.9 % |
|
Alzheimer's disease |
March 2010 | £2115 | 4.9 % |
|
Point of Care Diagnostics: Players, Products & Future Market Prospects |
November 2009 | £995 | 4.9 % |
|
Cell Therapy Technologies, Markets and Companies |
March 2010 | £3300 | 4.9 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
October 2009 | £1980 | 4.9 % |
|
Alzheimer's disease New Drugs, Markets and Companies |
October 2009 | £1980 | 4.9 % |
|
Achieving success in the Developing Asian Pharmaceutical Sector 2007-2011 |
November 2006 | £1999 | 4.9 % |
|
The Spanish Blood Banking Market through 2013 |
September 2009 | £2710 | 4.2 % |
|
Italian Infectious Disease Testing Market |
November 2009 | £0 | 4.2 % |
|
Molecular Diagnostics Technologies, Markets and Companies |
March 2010 | £3300 | 4.2 % |
|
UK Infectious Disease Testing Market |
November 2009 | £0 | 4.2 % |
|
The French Blood Banking Market through 2013 |
September 2009 | £2710 | 4.2 % |
|
The UK Blood Banking Market through 2013 |
September 2009 | £2710 | 4.2 % |
|
Personalized Medicine Scientific & Commercial Aspects |
March 2010 | £2640 | 4.2 % |
|
The German Blood Banking Market through 2013 |
September 2009 | £2710 | 4.2 % |
|
The Executive Guide to Molecular Imaging |
July 2007 | £595 | 4.2 % |
|
Nutraceuticals and Dietary Supplements Markets |
September 2007 | £2245 | 4.2 % |
|
In Vitro Diagnostics Market Report & Analysis 2008-2023 |
June 2008 | £1499 | 4.2 % |
|
French Infectious Disease Testing Market |
November 2009 | £0 | 4.2 % |
|
German Infectious Disease Testing Market |
November 2009 | £0 | 4.2 % |
|
Japanese Infectious Disease Testing Market |
November 2009 | £0 | 4.2 % |
|
The Italian Blood Banking Market through 2013 |
September 2009 | £2710 | 4.2 % |
|
Spanish Infectious Disease Testing Market |
November 2009 | £0 | 4.2 % |
|
The Japanese Blood Banking Market through 2013 |
September 2009 | £3630 | 4.2 % |
|
US Infectious Disease Testing Market |
November 2009 | £0 | 4.2 % |
|
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012 |
April 2007 | £1499 | 3.85 % |
|
Nitric Oxide Therapeutics, Markets and Companies |
March 2010 | £1850 | 3.85 % |
|
Global Vaccines Market 2008-2023, The |
August 2008 | £1499 | 3.85 % |
|
Molecular Diagnostics Markets |
September 2008 | £2245 | 3.85 % |
|
Immunotherapy of Cancer |
March 2007 | £3205 | 3.85 % |
|
Oncology Market Leaders Analyses and Outlook, Market Report 2008 - 2023 |
October 2008 | £1499 | 3.85 % |
|
Human Vaccines Global Market Opportunities |
November 2009 | £1980 | 3.85 % |
|
CNS Generic Drugs: Prospects and Opportunities to 2012 |
April 2008 | £995 | 2.8 % |
